European Commission approves Pfizer’s first oncology biosimilar
Pfizer Inc. today announced the European Commission has approved TRAZIMERA, a biosimilar to Herceptin (trastuzumab), for the treatment of human epidermal growth factor overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
More... |
Re: European Commission approves Pfizer’s first oncology biosimilar
Yeah!
Another one approved. |
All times are GMT -7. The time now is 09:57 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021